Boehringer Ingelheim Buys Rights to Enleofen’s Fibro-inflammatory Anti-IL-11 Platform
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 1 (Table of Contents)
Published: 14 Jan-2020
DOI: 10.3833/pdr.v2020.i1.2498 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Continuing to expand its fibrotic disease franchise, Boehringer Ingelheim (BI) has acquired the rights to Enleofen’s preclinical interleukin-11 platform in which the latter is eligible to receive in excess of US$1 B in terms of upfront and additional milestone payments per product...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS